Earlier this year, the Department of Defense released two annual reports on the status of its chemical and biological defense efforts (both pdf):
“Department of Defense Chemical and Biological Defense Program,” Annual Report to Congress, April 2007.
“Report on Activities and Programs for Countering Proliferation and NBC Terrorism,” Counterproliferation Program Review Committee, Volume I, Executive Summary, May 2007.
Nuclear weapons budgeting is like agreeing to buying a house without knowing the sales price, the mortgage rate, or the monthly payment.
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.